Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility

Authors: Benedicte Stavik, Grethe Skretting, Hans-Christian Aasheim, Mari Tinholt, Lillian Zernichow, Marit Sletten, Per Morten Sandset, Nina Iversen

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Increased hemostatic activity is common in many cancer types and often causes additional complications and even death. Circumstantial evidence suggests that tissue factor pathway inhibitor-1 (TFPI) plays a role in cancer development. We recently reported that downregulation of TFPI inhibited apoptosis in a breast cancer cell line. In this study, we investigated the effects of TFPI on self-sustained growth and motility of these cells, and of another invasive breast cancer cell type (MDA-MB-231).

Methods

Stable cell lines with TFPI (both α and β) and only TFPIβ downregulated were created using RNA interference technology. We investigated the ability of the transduced cells to grow, when seeded at low densities, and to form colonies, along with metastatic characteristics such as adhesion, migration and invasion.

Results

Downregulation of TFPI was associated with increased self-sustained cell growth. An increase in cell attachment and spreading was observed to collagen type I, together with elevated levels of integrin α2. Downregulation of TFPI also stimulated migration and invasion of cells, and elevated MMP activity was involved in the increased invasion observed. Surprisingly, equivalent results were observed when TFPIβ was downregulated, revealing a novel function of this isoform in cancer metastasis.

Conclusions

Our results suggest an anti-metastatic effect of TFPI and may provide a novel therapeutic approach in cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bouillaud S: De l'Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med. 1823, 1: 188-204. Bouillaud S: De l'Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med. 1823, 1: 188-204.
2.
go back to reference Trousseau A: Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris. Edited by: Trousseau A. 1865, Paris: Balliere J.-B.et fils, 654-712. 2 Trousseau A: Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris. Edited by: Trousseau A. 1865, Paris: Balliere J.-B.et fils, 654-712. 2
3.
go back to reference Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW: Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007, 5: 246-254.CrossRefPubMed Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW: Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007, 5: 246-254.CrossRefPubMed
4.
go back to reference Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP: Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001, 86: 959-972.PubMed Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP: Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001, 86: 959-972.PubMed
5.
go back to reference Price GC, Thompson SA, Kam PCA: Tissue factor and tissue factor pathway inhibitor. Anaesthesia. 2004, 59: 483-492. 10.1111/j.1365-2044.2004.03679.x.CrossRefPubMed Price GC, Thompson SA, Kam PCA: Tissue factor and tissue factor pathway inhibitor. Anaesthesia. 2004, 59: 483-492. 10.1111/j.1365-2044.2004.03679.x.CrossRefPubMed
6.
go back to reference Lindahl AK, Sandset PM, Abildgaard U, Andersson TR, Harbitz TB: High Plasma-Levels of Extrinsic Pathway Inhibitor and Low-Levels of Other Coagulation Inhibitors in Advanced Cancer. Acta Chir Scand. 1989, 155: 389-393.PubMed Lindahl AK, Sandset PM, Abildgaard U, Andersson TR, Harbitz TB: High Plasma-Levels of Extrinsic Pathway Inhibitor and Low-Levels of Other Coagulation Inhibitors in Advanced Cancer. Acta Chir Scand. 1989, 155: 389-393.PubMed
7.
go back to reference Iversen N, Lindahl AK, Abildgaard U: Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol. 1998, 102: 889-895. 10.1046/j.1365-2141.1998.00875.x.CrossRefPubMed Iversen N, Lindahl AK, Abildgaard U: Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol. 1998, 102: 889-895. 10.1046/j.1365-2141.1998.00875.x.CrossRefPubMed
8.
go back to reference Kurer MA: Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep. 2007, 34: 221-224. 10.1007/s11033-006-9036-4.CrossRefPubMed Kurer MA: Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep. 2007, 34: 221-224. 10.1007/s11033-006-9036-4.CrossRefPubMed
9.
go back to reference Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W: Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost. 2010, 103: 198-204.CrossRefPubMed Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W: Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost. 2010, 103: 198-204.CrossRefPubMed
10.
go back to reference Lwaleed BA, Bass PS: Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006, 208: 327-339. 10.1002/path.1871.CrossRefPubMed Lwaleed BA, Bass PS: Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006, 208: 327-339. 10.1002/path.1871.CrossRefPubMed
11.
go back to reference Zhang J, Piro O, Lu L, Broze GJ: Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation. 2003, 108: 623-627. 10.1161/01.CIR.0000078642.45127.7B.CrossRefPubMed Zhang J, Piro O, Lu L, Broze GJ: Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation. 2003, 108: 623-627. 10.1161/01.CIR.0000078642.45127.7B.CrossRefPubMed
12.
go back to reference Maroney SA, Cunningham AC, Ferrel J, Hu R, Haberichter S, Mansbach CM, Brodsky RA, Dietzen DJ, Mast AE: A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost. 2006, 4: 1114-1124. 10.1111/j.1538-7836.2006.01873.x.CrossRefPubMed Maroney SA, Cunningham AC, Ferrel J, Hu R, Haberichter S, Mansbach CM, Brodsky RA, Dietzen DJ, Mast AE: A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost. 2006, 4: 1114-1124. 10.1111/j.1538-7836.2006.01873.x.CrossRefPubMed
13.
go back to reference Piro O, Broze GJ: Comparison of cell-surface TFPI alpha and beta. J Thromb Haemost. 2005, 3: 2677-2683. 10.1111/j.1538-7836.2005.01636.x.CrossRefPubMed Piro O, Broze GJ: Comparison of cell-surface TFPI alpha and beta. J Thromb Haemost. 2005, 3: 2677-2683. 10.1111/j.1538-7836.2005.01636.x.CrossRefPubMed
14.
go back to reference Crawley JTB, Lane DA: The Haemostatic Role of Tissue Factor Pathway Inhibitor. Arterioscler Thromb Vasc Biol. 2008, 28: 233-242.CrossRefPubMed Crawley JTB, Lane DA: The Haemostatic Role of Tissue Factor Pathway Inhibitor. Arterioscler Thromb Vasc Biol. 2008, 28: 233-242.CrossRefPubMed
15.
go back to reference Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N: Overexpression of both TFPIalpha and TFPIbeta induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. Mol Carcinog. 2010, 49: 951-963. 10.1002/mc.20679.CrossRefPubMed Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N: Overexpression of both TFPIalpha and TFPIbeta induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. Mol Carcinog. 2010, 49: 951-963. 10.1002/mc.20679.CrossRefPubMed
16.
go back to reference Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS: Tissue Factor/Factor VIIa Inhibitors Block Angiogenesis and Tumor Growth Through a Nonhemostatic Mechanism. Cancer Res. 2003, 63: 2997-3000.PubMed Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS: Tissue Factor/Factor VIIa Inhibitors Block Angiogenesis and Tumor Growth Through a Nonhemostatic Mechanism. Cancer Res. 2003, 63: 2997-3000.PubMed
17.
go back to reference Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL: Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost. 2002, 87: 930-936.PubMed Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL: Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost. 2002, 87: 930-936.PubMed
18.
go back to reference Hamuro T, Kamikubo Y, Nakahara Y, Miyamoto S, Funatsu A: Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett. 1998, 421: 197-202. 10.1016/S0014-5793(97)01559-7.CrossRefPubMed Hamuro T, Kamikubo Y, Nakahara Y, Miyamoto S, Funatsu A: Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett. 1998, 421: 197-202. 10.1016/S0014-5793(97)01559-7.CrossRefPubMed
19.
go back to reference Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK: Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem. 2001, 276: 12241-12248. 10.1074/jbc.M010395200.CrossRefPubMed Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK: Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem. 2001, 276: 12241-12248. 10.1074/jbc.M010395200.CrossRefPubMed
20.
go back to reference Kamikubo Yi, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A: Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. 1997, 407: 116-120. 10.1016/S0014-5793(97)00312-8.CrossRefPubMed Kamikubo Yi, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A: Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. 1997, 407: 116-120. 10.1016/S0014-5793(97)00312-8.CrossRefPubMed
21.
go back to reference Liang W, Cheng J, Liu R, Wang Jp, Mu Jg, Wang Qh, Wang Hj, Ma D: Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo. Peptides. 2009, 30: 2330-2336. 10.1016/j.peptides.2009.08.016.CrossRefPubMed Liang W, Cheng J, Liu R, Wang Jp, Mu Jg, Wang Qh, Wang Hj, Ma D: Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo. Peptides. 2009, 30: 2330-2336. 10.1016/j.peptides.2009.08.016.CrossRefPubMed
22.
go back to reference Lin YF, Zhang N, Guo HS, Kong DS, Jiang T, Liang W, Zhao ZH, Tang QQ, Ma D: Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway. Apoptosis. 2007, 12: 2163-2173. 10.1007/s10495-007-0136-y.CrossRefPubMed Lin YF, Zhang N, Guo HS, Kong DS, Jiang T, Liang W, Zhao ZH, Tang QQ, Ma D: Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway. Apoptosis. 2007, 12: 2163-2173. 10.1007/s10495-007-0136-y.CrossRefPubMed
23.
go back to reference Shirotani-Ikejima H, Kokame K, Hamuro T, Bu G, Kato H, Miyata T: Tissue factor pathway inhibitor induces expression of JUNB and GADD45B mRNAs. Biochem Biophys Res Commun. 2002, 299: 847-852. 10.1016/S0006-291X(02)02759-6.CrossRefPubMed Shirotani-Ikejima H, Kokame K, Hamuro T, Bu G, Kato H, Miyata T: Tissue factor pathway inhibitor induces expression of JUNB and GADD45B mRNAs. Biochem Biophys Res Commun. 2002, 299: 847-852. 10.1016/S0006-291X(02)02759-6.CrossRefPubMed
24.
go back to reference Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS: Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood. 2004, 103: 3374-3380. 10.1182/blood-2003-07-2234.CrossRefPubMed Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS: Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood. 2004, 103: 3374-3380. 10.1182/blood-2003-07-2234.CrossRefPubMed
25.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
26.
go back to reference Felding-Habermann B: Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis. 2003, 20: 203-213. 10.1023/A:1022983000355.CrossRefPubMed Felding-Habermann B: Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis. 2003, 20: 203-213. 10.1023/A:1022983000355.CrossRefPubMed
27.
go back to reference Panetti TS: Tyrosine phosphorylation of paxillin, FAK, and p130CAS: Effects on cell spreading and migration. Front Biosci. 2002, 7: D143-D150. 10.2741/panetti.PubMed Panetti TS: Tyrosine phosphorylation of paxillin, FAK, and p130CAS: Effects on cell spreading and migration. Front Biosci. 2002, 7: D143-D150. 10.2741/panetti.PubMed
28.
go back to reference Defilippi P, Olivo C, Venturino M, Dolce L, Silengo L, Tarone G: Actin cytoskeleton organization in response to integrin-mediated adhesion. Microsc Res Tech. 1999, 47: 67-78. 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.0.CO;2-P.CrossRefPubMed Defilippi P, Olivo C, Venturino M, Dolce L, Silengo L, Tarone G: Actin cytoskeleton organization in response to integrin-mediated adhesion. Microsc Res Tech. 1999, 47: 67-78. 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.0.CO;2-P.CrossRefPubMed
29.
go back to reference Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89: 1260-1270. 10.1093/jnci/89.17.1260.CrossRefPubMed Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89: 1260-1270. 10.1093/jnci/89.17.1260.CrossRefPubMed
30.
go back to reference Storvold GL, Gjernes E, Askautrud HA, Borresen-Dale AL, Perou CM, Frengen E: A retroviral vector for siRNA expression in mammalian cells. Mol Biotechnol. 2007, 35: 275-282. 10.1007/BF02686013.CrossRefPubMed Storvold GL, Gjernes E, Askautrud HA, Borresen-Dale AL, Perou CM, Frengen E: A retroviral vector for siRNA expression in mammalian cells. Mol Biotechnol. 2007, 35: 275-282. 10.1007/BF02686013.CrossRefPubMed
31.
go back to reference Winberg JO, Berg E, Kolset SO, Uhlin-Hansen L: Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur J Biochem. 2003, 270: 3996-4007. 10.1046/j.1432-1033.2003.03788.x.CrossRefPubMed Winberg JO, Berg E, Kolset SO, Uhlin-Hansen L: Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur J Biochem. 2003, 270: 3996-4007. 10.1046/j.1432-1033.2003.03788.x.CrossRefPubMed
32.
go back to reference McCall-Culbreath KD, Zutter MM: Collagen receptor integrins: Rising to the challenge. Curr Drug Targets. 2008, 9: 139-149. 10.2174/138945008783502494.CrossRefPubMed McCall-Culbreath KD, Zutter MM: Collagen receptor integrins: Rising to the challenge. Curr Drug Targets. 2008, 9: 139-149. 10.2174/138945008783502494.CrossRefPubMed
33.
go back to reference Stefansson S, Lawrence DA: Old Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration. Sci STKE. 2003, 2003: e24- Stefansson S, Lawrence DA: Old Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration. Sci STKE. 2003, 2003: e24-
34.
go back to reference Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000, 57: 25-40. 10.1007/s000180050497.CrossRefPubMed Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000, 57: 25-40. 10.1007/s000180050497.CrossRefPubMed
35.
go back to reference Provencal M, Michaud M, Beaulieu E, Ratel D, Rivard GE, Gingras D, Beliveau R: Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins. Thromb Haemost. 2008, 99: 576-585.PubMed Provencal M, Michaud M, Beaulieu E, Ratel D, Rivard GE, Gingras D, Beliveau R: Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins. Thromb Haemost. 2008, 99: 576-585.PubMed
36.
go back to reference Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV: Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004, 103: 3029-3037. 10.1182/blood-2003-10-3417.CrossRefPubMedPubMedCentral Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV: Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004, 103: 3029-3037. 10.1182/blood-2003-10-3417.CrossRefPubMedPubMedCentral
37.
go back to reference Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RC: Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg. 1999, 86: 890-894. 10.1046/j.1365-2168.1999.01153.x.CrossRefPubMed Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RC: Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg. 1999, 86: 890-894. 10.1046/j.1365-2168.1999.01153.x.CrossRefPubMed
38.
go back to reference Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005, 105: 1734-1741. 10.1182/blood-2004-05-2042.CrossRefPubMed Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005, 105: 1734-1741. 10.1182/blood-2004-05-2042.CrossRefPubMed
39.
go back to reference Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W: Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008, 111: 190-199. 10.1182/blood-2007-07-101048.CrossRefPubMedPubMedCentral Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W: Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008, 111: 190-199. 10.1182/blood-2007-07-101048.CrossRefPubMedPubMedCentral
40.
go back to reference Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT, Anderson GM: CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer. 2007, 120: 1261-1267. 10.1002/ijc.22426.CrossRefPubMed Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT, Anderson GM: CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer. 2007, 120: 1261-1267. 10.1002/ijc.22426.CrossRefPubMed
41.
go back to reference Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ: Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med. 2004, 10: 6-11. 10.1007/s00894-003-0157-6.CrossRefPubMedPubMedCentral Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ: Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med. 2004, 10: 6-11. 10.1007/s00894-003-0157-6.CrossRefPubMedPubMedCentral
42.
go back to reference Trotter J, Klein C, Kramer EM: GPI-anchored proteins and glycosphingolipid-rich rafts: Platforms for adhesion and signaling. Neuroscientist. 2000, 6: 271-284. 10.1177/107385840000600410.CrossRef Trotter J, Klein C, Kramer EM: GPI-anchored proteins and glycosphingolipid-rich rafts: Platforms for adhesion and signaling. Neuroscientist. 2000, 6: 271-284. 10.1177/107385840000600410.CrossRef
43.
go back to reference Horejsi V, Drbal K, Cebecauer M, Cerny J, Brdicka T, Angelisova P, Stockinger H: GPI-microdomains: a role in signalling via immunoreceptors. Immunol Today. 1999, 20: 356-361. 10.1016/S0167-5699(99)01489-9.CrossRefPubMed Horejsi V, Drbal K, Cebecauer M, Cerny J, Brdicka T, Angelisova P, Stockinger H: GPI-microdomains: a role in signalling via immunoreceptors. Immunol Today. 1999, 20: 356-361. 10.1016/S0167-5699(99)01489-9.CrossRefPubMed
44.
go back to reference Paulick MG, Bertozzi CR: The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry. 2008, 47: 6991-7000. 10.1021/bi8006324.CrossRefPubMedPubMedCentral Paulick MG, Bertozzi CR: The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry. 2008, 47: 6991-7000. 10.1021/bi8006324.CrossRefPubMedPubMedCentral
45.
go back to reference Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H: GPI-Anchored Cell-Surface Molecules Complexed to Protein Tyrosine Kinases. Science. 1991, 254: 1016-1019. 10.1126/science.1719635.CrossRefPubMed Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H: GPI-Anchored Cell-Surface Molecules Complexed to Protein Tyrosine Kinases. Science. 1991, 254: 1016-1019. 10.1126/science.1719635.CrossRefPubMed
46.
go back to reference Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV, Lupu F: Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol. 1997, 17: 2964-2974. 10.1161/01.ATV.17.11.2964.CrossRefPubMed Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV, Lupu F: Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol. 1997, 17: 2964-2974. 10.1161/01.ATV.17.11.2964.CrossRefPubMed
47.
go back to reference Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000, 1: 31-39. 10.1038/35036052.CrossRefPubMed Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000, 1: 31-39. 10.1038/35036052.CrossRefPubMed
Metadata
Title
Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility
Authors
Benedicte Stavik
Grethe Skretting
Hans-Christian Aasheim
Mari Tinholt
Lillian Zernichow
Marit Sletten
Per Morten Sandset
Nina Iversen
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-357

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine